Skip to main content
SpringerLink
Log in

Use of Angiotensin Receptor Blockers in the Elderly

  • Chapter
Book cover Hypertension in the Elderly

Part of the book series: Clinical Hypertension and Vascular Diseases ((CHVD))

  • 806 Accesses

Abstract

No class of drugs has been more popular than the angiotensin-receptor blockers (ARBs). Their side-effect profile has resulted in increasing prescriptions because they are better tolerated than any other class of antihypertensive drugs. The outcome trials (Table 1) with these drugs are now being reported and are showing benefits for target organ protection (1–15). ARBs are proven to be effective in reducing the rate of renal insufficiency among diabetic hypertensives (3,5), reducing strokes for elderly patients (10) and hypertensive patients with left ventricular hypertrophy (7), and reducing cardiovascular mortality and total mortality compared to atenolol in diabetic hypertensive patients (9). Valsartan is as effective as captopril in patients sustaining a myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (15).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan vs captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747–752.

    Article  PubMed  CAS  Google Scholar 

  2. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582–1587.

    Article  PubMed  CAS  Google Scholar 

  3. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.

    Article  PubMed  CAS  Google Scholar 

  4. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. NEngl J Med 2001;345:1667–1675.

    Article  CAS  Google Scholar 

  5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.

    Article  PubMed  CAS  Google Scholar 

  6. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878.

    Article  PubMed  CAS  Google Scholar 

  7. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  8. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan. Lancet 2002;360:752–760.

    Article  PubMed  CAS  Google Scholar 

  9. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  10. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of arandomized double-blind intervention trial. J Hypertens 2003;21:875–886.

    Article  PubMed  CAS  Google Scholar 

  11. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–766.

    Article  PubMed  CAS  Google Scholar 

  12. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–771.

    Article  PubMed  CAS  Google Scholar 

  13. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–776.

    Article  PubMed  CAS  Google Scholar 

  14. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781.

    Article  PubMed  CAS  Google Scholar 

  15. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906.

    Article  PubMed  CAS  Google Scholar 

  16. Prisant LM. Angioneurotic edema. J Clin Hypertens (Greenwich) 2001;3:262–263.

    Article  CAS  Google Scholar 

  17. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997;11(suppl 2):S19–S25.

    PubMed  Google Scholar 

  18. McInnes GT, O’Kane KP, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997;11(suppl2):S75–S80.

    PubMed  CAS  Google Scholar 

  19. Neldam S, Forsen B. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging 2001;18:225–232.

    Article  PubMed  CAS  Google Scholar 

  20. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002;15:544–549.

    Article  PubMed  CAS  Google Scholar 

  21. Schrader J, Luders S, Kulschewski A, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003;34:1699–1703.

    Article  PubMed  Google Scholar 

  22. Tenero DM, Martin DE, Miller AK, et al. Effect of age and gender on the pharmacokinetics of eprosartan. Br J Clin Pharmacol 1998;46:267–270.

    Article  PubMed  CAS  Google Scholar 

  23. Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin 1999;15:9–14.

    Article  PubMed  CAS  Google Scholar 

  24. Ruilope L, Jager B, Prichard B. Eprosartan vs enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press 2001;10:223–229.

    Article  PubMed  CAS  Google Scholar 

  25. Vachharajani NN, Shyu WC, Smith RA, Greene DS. The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol 1998;46:611–613.

    Article  PubMed  CAS  Google Scholar 

  26. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997;54:885–902.

    PubMed  CAS  Google Scholar 

  27. De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A. Evaluation of long-term efficacy and tolerability of irbesartan in elderly hypertensive patients with renal impairment in an open-label study. Curr Ther Res 2002;63:201–215.

    Article  Google Scholar 

  28. Pool JL, Guthrie RM, Littlejohn TW 3rd, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998;11(4 pt 1):462–470.

    Article  PubMed  CAS  Google Scholar 

  29. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999;12(8 pt 1):797–805.

    Article  PubMed  CAS  Google Scholar 

  30. Lacourciere Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther 2000;22:1213–1224.

    Article  PubMed  CAS  Google Scholar 

  31. Schaefer KL, Porter JA. Angiotensin II receptor antagonists: the prototype losartan. Ann Pharmacother 1996;30:625–636.

    PubMed  CAS  Google Scholar 

  32. Farsang C, Garcia-Puig J, Niegowska J, Baiz AQ, Vrijens F, Bortman G. The efficacy and tolerability of losartan vs atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. J Hypertens 2000;18:795–801.

    Article  PubMed  CAS  Google Scholar 

  33. Fernández-Vega F, Abellan J, Sanz de Castro S, Cucalón JM, Maceira B, Gomez de la Cámara A. A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension. Int Urol Nephrol 2001;32:519–523.

    Article  PubMed  Google Scholar 

  34. Chan JC, Critchley JA, Lappe JT, et al. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995;9:765–771.

    PubMed  CAS  Google Scholar 

  35. Conlin PR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM. A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. J Hum Hypertens 1998;12:693–699.

    Article  PubMed  CAS  Google Scholar 

  36. Critchley JAJH, Gilchrist N, Ikeda L, et al. A randomized, double-masked comparison of the antihypertensive efficacy and safety of combination therapy with losartan and hydrochlorothiazide vs captopril and hydrochlorothiazide in elderly and younger patients. Curr Ther Res 1996;57:392–407.

    Article  CAS  Google Scholar 

  37. von Bergmann K, Laeis P, Puchler K, Sudhop T, Schwocho LR, Gonzalez L. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl 2001;19(suppl 1):S33–S40.

    Google Scholar 

  38. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87:37C–43C.

    Article  PubMed  CAS  Google Scholar 

  39. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149–167.

    PubMed  CAS  Google Scholar 

  40. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide vs telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23:833–850.

    Article  PubMed  CAS  Google Scholar 

  41. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999;17:293–302.

    Article  PubMed  CAS  Google Scholar 

  42. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998;19:237–244.

    Article  PubMed  CAS  Google Scholar 

  43. Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged > or = 65 years with systolic hypertension. Clin Ther 2000;22:961–969.

    Article  PubMed  CAS  Google Scholar 

  44. Hedner T, Pool JL, Oparil S, Glazer R, Chiang Y. Valsartan provides effective antihypertensive response in older patients: an integrated analysis. J Hypertens 2000;18(suppl2):S42.

    Google Scholar 

  45. Bremner AD, Mehring GH, Meilenbrock S. Long-term systemic tolerability of valsartan compared with lisinopril in elderly hypertensive patients. Adv Ther 1997;14:245–253.

    CAS  Google Scholar 

  46. Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997;19:1263–1285.

    Article  PubMed  CAS  Google Scholar 

  47. Malacco E, Vari N, Capuano V, Spagnuolo V, Borgnino C, Palatini P. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003;25:2765–2780.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension and Clinical Pharmacology, Department of Medicine, Medical College of Georgia, Augusta, GA

    L. Michael Prisant MD (FACC, FACP, FAHA)

Authors
  1. L. Michael Prisant MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical College of Georgia, Augusta, GA

    L. Michael Prisant MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Prisant, L.M. (2005). Use of Angiotensin Receptor Blockers in the Elderly. In: Prisant, L.M. (eds) Hypertension in the Elderly. Clinical Hypertension and Vascular Diseases. Humana Press. https://doi.org/10.1007/978-1-59259-911-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-911-0_17

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-197-4

  • Online ISBN: 978-1-59259-911-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation